Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Touts Synergy Bioabsorbable Polymer Stent Trial Data

This article was originally published in The Gray Sheet

Executive Summary

Principle investigator on the Evolve II trial is optimistic the stent will dominate the U.S. market in two to three years.

You may also be interested in...



Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US

Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its Synergy drug-eluting stent that they expect will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease. "Our belief is that the target for Synergy is [the] entire market," says Boston Scientific's senior VP and president of its interventional cardiology unit.

Boston Sci Says It Will Be Careful About Resorbable Scaffold Investment

The company announced July 20 the start of its 30-patient, single-arm FAST study assessing its everolimus-eluting scaffold system, but executives says Boston Scientific will be closely considering whether the system warrants long-term investment, considering the promise of its Synergy stent.

Abbott Submits PMA For Absorb Bioresorbable Scaffold

The firm's FDA submission for the first-in-class bioresorbable vascular scaffold was completed in the second quarter, a spokesman said. That appears to be ahead of a prior estimate to submit by the end of 2015.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT033509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel